Amide Active Ingredients TRIZ Cases

A two-phase HCM regimen uses mavacamten to reduce hypercontractility while tapering beta blockers, improving exercise capacity and symptoms.

Combining HDAC inhibition, stem-cell-based vaccination, and a TLR3 adjuvant boosts MHC-I antigen presentation to target resistant cancer stem cells.

Prodrug STAT3 inhibitors block pathogenic IL-6/STAT3 signaling to restore Teff/Treg balance, reduce IL-17, and suppress autoimmunity.

Fumaric acid esters raise fetal hemoglobin through an alternative pathway to ease sickle cell symptoms with fewer hydroxyurea-related risks.

Combining LSD1 inhibitors with CDK4/6 inhibitors or p21 enhancers helps overcome p21-linked resistance and suppress cancer cell proliferation.

A combined HDAC inhibitor and ER antagonist triggers Par-4/GRP78-mediated apoptosis in drug-resistant glioma cells and cancer stem cells.

Controlled hydroxyurea dosing raises hemoglobin in severe chronic anemia from sickle cell disease while avoiding myelosuppression.

Mechanical thrombectomy combined with a SUR1-TRPM4 inhibitor is used to reduce brain edema and limit late neurological deterioration after ischemic stroke.

mPEG-PDLLA nanoparticles target romidepsin delivery to tumors, limiting off-target toxicity during combination therapy.

A 0.2 mg tamsulosin dose every 48 hours uses reversible receptor blockade to slow seminal secretion and transport, delaying ejaculation.

Rapid resistance limits MEK inhibitors in KRAS-driven pancreatic cancer; this case combines MEK and multi-kinase agents to block compensatory signaling.

KRAS-G12D tumors lack targeted options; AST-3424 uses AKR1C3 activation to release a selective DNA-alkylating agent.

A KAT6 inhibitor combined with CDK4/6 inhibition and/or fulvestrant addresses resistance in HR+ breast cancer and reduces side effects.

Reducing intratumoral iron with chelators alongside CHK1 or ATR inhibitors strengthens DNA damage and apoptosis in CRC.

This case combines BRG1/BRM reduction with corticosteroids, hydroxyurea, furosemide, or leukapheresis to manage symptoms.

A p53 activator with SMAD4 and ERK inhibitors reverses EMT, helping cancer cells regain chemotherapy sensitivity and limiting metastasis.

Administering CDK1 inhibitors to mammary alveolar cells triggers endoreplication and increases polyploid cell counts.

Dual MEK and CDK4/6 inhibition triggers SASP to normalize tumor vasculature, overcoming drug delivery barriers in pancreatic cancer.

Multilayered ceramide lamellar structure stabilizes lipid components using glucoside surfactants for enhanced water holding capacity.

Compounds bind pathogenic CUG repeat RNA to trigger nuclear export, releasing sequestered splicing factors and correcting mis-splicing in myotonic dystrophy.

Administering a super elongation complex inhibitor targets aberrant pathways to treat blood cancers.

Novel organo-selenium compounds resolve synthesis difficulties by enabling industrial-scale production of stable anti-tumor agents.

Combining selective Raf inhibitor with trametinib blocks tumorigenesis, improving clinical activity while reducing adverse side effects in RAS-mutant cancers.

Segmenting the tablet prevents solifenacin dissolution delays caused by hydrogel formation, maintaining bioavailability while improving dosing compliance.

Specific Formula I compounds disrupt the KEAP1-NRF2 interaction to resolve contradictions between inhibition activity and target safety.

Cross-linked carbomers manage tablet size to improve swallowability while sustaining acamprosate release and reducing dose dumping.

A multi-component dietary supplement with Palmitoylethanolamide and Boswellia reduces inflammatory cytokines, providing systemic relief without side effects.

Compositions targeting androgen receptors overcome therapy resistance in cancer.

Sequential histone deacetylase inhibitor and MAPK pathway inhibitor therapy overcomes resistance in BRAF or NRAS mutated melanoma.

A skin treatment compound combines lidocaine with aloe vera to deliver pain relief and accelerate healing.

Oral statin and antifibrotic tablet reduces repeated pancreatitis attacks and pancreatic cancer risk.

Topical organic compounds interrupt systemic drug binding to skin targets, maintaining cancer treatment continuity without dose reduction.

BME and SISgel 3D cultures model physiological conditions to screen agents targeting dormant cells, preventing recurrence.

A USP24 inhibitor blocks ABC transporter stabilization to restore chemosensitivity in resistant cancer cells.

Optimized excipient particle sizes resolve physicochemical incompatibility between nimesulide and thiocolchicoside in a single monolayer tablet.

A triple-layer tablet design uses an intermediate water-absorbing layer to release tamsulosin in the lower digestive tract.

Antisense oligonucleotides silence MGMT expression to restore temozolomide sensitivity in glioblastoma, preventing tumor recurrence.

Compounds bind ENPP1 extracellular domain zinc sites to inhibit enzymatic activity at physiological pH.

Combining these compounds with PI3Kδ-selective inhibitors overcomes resistance mechanisms in aggressive lymphoma subtypes.

Administering cognitive enhancing agents to domestic animals accelerates the learning process during conditioning sessions.

Rate controlling polymers in thiocolchicoside formulations prevent dose dumping and maintain constant plasma concentrations for improved patient compliance.

Selective alpha-1A adrenergic receptor antagonists block prefrontal cortical deficits while avoiding hypotension and sedation side effects.

Targeting CAMK2G in sympathetic nerves with ICI 118551 reduces IL-17 mediated immune responses, addressing unpredictable psoriasis treatment outcomes.

Topical HIF-1α stabilizer nanoparticles resolve anastomotic ischemia by promoting microvascular perfusion.

Administering necroptosis inhibitors blocks RIP1-RIP3-MLKL pathways to maintain testosterone levels and fertility while preventing muscle mass loss.

Chromanol compounds mitigate heart failure with reduced ejection fraction by reducing fibrosis, oxidative stress, and maintaining mitochondrial activity.

Thiourea derivatives inhibit efflux pumps and alter membrane potential, reversing multidrug resistance in Staphylococcus aureus infections.